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Background: Vascular events represent the most frequent complications of thrombocytemias. We aimed to
evaluate their risk in the WHO histologic categories of Essential Thrombocytemia (ET) and early Primary
Myelofibrosis (PMF).
Methods: From our clinical database of 283 thrombocytemic patients, we selected those with available bone
marrow histology performed before any treatment, at or within 1 year from diagnosis, and reclassified the 131
cases as true ET or early PMF, with or without fibrosis, according to the WHO histological criteria. Vaso-occlusive
events at diagnosis and in the follow-up were compared in the WHO-groups.
Results: Histologic review reclassified 61 cases as ET and 72 cases as early PMF (26 prefibrotic and 42 with grade 1
or 2 fibrosis). Compared to ET, early PMF showed a significant higher rate of thrombosis both in the past history
(22% vs 8%) and at diagnosis (15.2% vs 1.6%), and an increased leukocyte count (8389 vs 7500/mmc). Venous
thromboses (mainly atypical) were relatively more common in PMF than in ET. Patients with prefibrotic PMF,
although younger, showed a significant higher 15-year risk of developing thrombosis (48% vs 16% in fibrotic PMF
and 17% in ET). At multivariate analysis, age and WHO histology were both independent risk-factors for thrombosis
during follow-up; patients >60 yr-old or with prefibrotic PMF showed a significantly higher risk at 20 years than
patients <60 yr-old with ET or fibrotic PMF (47% vs 4%, p = 0.005).
Conclusions: Our study support the importance of WHO histologic categories in the thrombotic risk stratification of
patients with thrombocytemias.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2020211863144412.
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interpretationBackground
Essential thrombocythemia (ET) is a clonal stem cell dis-
order that shares several similarities with other myelo-
proliferative neoplasms (MPNs), particularly polycythemia
vera (PV) and primary myelofibrosis (PMF) [1]. The* Correspondence: g.goteri@univpm.it
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unless otherwise stated.discrimination between Essential Thrombocythemia
(ET) and the early Primary Myelofibrosis (PMF) is es-
pecially crucial because it can influence the diagnostic
strategies, outcome and complications [2]. The updated
WHO classification integrates clinical, molecular and
pathological criteria, but the fine morphologic examin-
ation of the bone marrow still maintains a central role
[3-5]: ET is characterized by a significant increase of
enlarged and mature megakaryocytes in a bone marrow
with normal cellularity, and normal maturation and
quantity of the other series, whereas PMF combines theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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creased cellularity, increased and left-shifted granulo-
poiesis, reduced erythropoiesis and/or reticulin and
collagen fibrosis. The issue of histologic reproducibility
in distinguishing the two diseases has been debated in
the literature since 2001 and is still of interest [6-13].
In the present study, we aimed to test the hypothesis
that our clinico-pathologic database of patients also
contains a mixture of biologically heterogeneous en-
tities with different natural history and clinical outcome
in terms of survival and thrombosis: the WHO-defined
ET (“true” ET) and early PMF, with different survival
and propensity to develop thrombosis during follow-
up. By observing a strict adherence to the WHO histo-
logic criteria and blind to clinical data, we reclassified
our series as “true” ET and early PMF, and subsequently
we subclassified early PMF cases as prefibrotic PMF
(grade 0 myelofibrosis) and fibrotic PMF (grade 1 and 2
myelofibrosis). For the significantly higher occurrence
of major thrombotic events during follow-up in prefi-
brotic PMF, we propose a new prognostic model for
thrombosis that was based on age and WHO histology.
Methods
A clinico-pathologic database of patients with complete
clinical data consecutively diagnosed as having ET and
treated at our institution has been reviewed. This study
included 283 patients with ET diagnosed since 1980 and
followed up to 2011 at the Clinic of Hematology Poly-
technic University of Marche Region, United Hospital of
Ancona, Italy. The diagnosis of ET was originally made
in accordance with the criteria in use at the time of first
observation. In the present study we considered the fol-
lowing parameters: age, sex, platelet count, hemoglobin
level, white blood cell count, lactic dehydrogenase
(LDH- evaluated in 95 patients), JAK2V617F mutation
status (investigated since 2007 in 75 patients), spleen
size, history of thrombosis (before and at diagnosis), pro-
gression to overt myelofibrosis, conventional risk for
thrombosis according to Cervantes [14]. We considered
as venous and arterial thrombotic events the following:
deep venous thrombosis of the extremities (DVT) or
atypical thrombosis (abdominal and cerebral veins), pul-
monary embolism (PE), ischemic stroke, cerebral transi-
ent ischemic attack (TIA), acute myocardial infarction
(AMI) and peripheral arterial thrombosis (PAT).
The histological review was done in cases in whom the
bone marrow trephine biopsy was performed before any
treatment, at or within 1 year from diagnosis. The histo-
logical review was performed on the original slides by a
pathologist with 20 year-experience on hematopathology
(G.G.) blind to the other clinical and follow-up data. At
the time of diagnosis the specimens had been fixed in
buffered formalin, decalcified in EDTA and paraffin-embedded. For assessment the histological sections had
been stained with hematoxylin and eosin (H&E), Giemsa,
periodic acid Schiff reagent (PAS), Prussian Blue and
Gomori’s silver impregnation. Of each specimen, the fol-
lowing parameters were considered according to Thiele
and Kvasnicka [6]: the overall bone marrow cellularity
compared to the age-matched control [15], the amount of
granulopoiesis, erythropoiesis and megakaryocytopoiesis
(scored as 0 for normal or reduced, 1 for slight increase, 2
for moderate increase, 3 for marked increase); left-shifted
maturation of erythroid and myeloid series (absent or
present); clusters of megakaryocytes (absent, loose or
dense); giant hyperlobulated or bulbous MGKs (absent,
rare or frequent); reticulin fibrosis according to a 4-graded
system [15]: 0 for scattered linear reticulin with no inter-
sections (cross-overs); 1 for a loose network of reticulin
with many intersections, especially in perivascular areas; 2
for diffuse and dense increase in reticulin with extensive
intersections, occasionally with only focal bundles of colla-
gen and/or focal osteosclerosis; 3 for diffuse and dense in-
crease in reticulin with extensive intersections with coarse
bundles of collagen, often associated with significant
osteosclerosis. In all cases immunostainings for myeloid,
erythroid and megacariocytic markers were also performed
to better evaluate these parameters. When necessary, histo-
chemical and immunohistochemical stainings were re-
peated. All cases were reclassified as “true” ET and early
PMF in their turn divided into prefibrotic PMF (grade 0
myelofibrosis) and fibrotic PMF (grade 1 and 2 myelofibro-
sis) according to 2008 WHO morphologic criteria [4,5].Statistical analysis
Statistical analysis was performed with SPSS software for
Windows (Statistical Product and Service Solutions, version
14.0, SSPS Inc, Chicago, IL, USA). The clinical and histo-
logic parameters were compared in the histological categor-
ies. Quantitative variables were expressed as mean values
and standard deviation (SD) for normally distributed data.
These data were compared using the Mann–Whitney test.
Differences between the qualitative variables were evaluated
using the chi-square test. P < 0.05 was considered statisti-
cally significant. The Kaplan-Meier product-limit method
was used to estimate univariate survival curves, and the
log-rank test was selected to compare the survival curves.
Cox proportional hazards regression was used to perform
multivariate survival analyses. Risk of thrombosis was re-
ported as by cumulative incidences calculated at 5, 10, 15
and 20 years from the date of diagnosis. Overall survival
(OS) analysis was considered from the date of diagnosis to
date of death or last contact. Event-free survival curves
were calculated from the date of diagnosis to date of
leukemic transformation or progression into overt myelofi-
brosis, or last contact/date of death.
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A total of 142 cases were considered for the present
study. In 61 (43%) the histology was consistent with a
diagnosis of ET (Figure 1A), 72 (51%) were revised to
early PMF (Figure 1B), and 9 cases (6%) were excluded
from the analysis as they did not exhibit discriminating
features between the two categories and considered as
unclassifiable MPNs. In PMF cases, 46 cases were fi-
brotic (grade 1 and 2) and 26 were prefibrotic (grade 0).
All early PMF with the exception of four cases, lacked
the minor clinical criteria for PMF stated in the WHO
classification (leukoerythroblastosis, increase in serum
LDH level, anemia, and splenomegaly). Median follow-
up from time of diagnosis was 117 months (95% C.I.,
103–144) for ET and 85 months (95% C.I., 85–119) for
early PMF (p not significant). Table 1 provides a com-
parison of the clinical, laboratory and histological pa-
rameters for patients with ET and those with early PMF.
Significant differences were seen for mean leukocyte count
(higher in early PMF than ET: 8389 vs 7500; p = 0.001),
history of thrombosis (more frequently in early PMF than
ET: 22% vs 8%; p = 0.032) and thrombosis at the onset of
disease (more frequently in early PMF than ET: 15.25% vs
1.6% respectively; p = 0.006). Mean semiquantitative score
referring to granulopoiesis was significantly different
(greater in early PMF than ET: 1.02 vs 0.15; p = 0.001);
moreover we found a significant correlation between gran-
ulopoiesis scores and thrombosis at the onset of disease
(Mann–Whitney test, 0.60 without thrombosis vs 1.10
with thrombosis, p < 0.05). JAK2V617F mutational fre-
quencies were also different between the two groups al-
though without statistical significance (greater in early
PMF than ET: 54% vs 33%; p = 0.06). On the contrary age,
sex distribution, anemia, LDH serum values, palpable
spleen and thrombotic complications during follow-up,
were similar between the two groups. Table 2 shows that
venous thrombosis (mainly atypical) were relatively com-
mon in early PMF, as opposed to ET. In this regard, it
must be pointed out that almost all of the abdominal
thrombosis (in total 5 cases out of six) were JAK2V617FFigure 1 H&E of bone marrow in ET (A) and in grade 0 Prefibrotic PMF (B). O
not increased, the megakaryocytes were mainly giant with stag-horn like nucl
cellularity was increased mainly for expansion of granulopoiesis; the megakarypositive. Table 3 describes the epidemiological and clinical
characteristics of the two PMF subgroups. Neither
hematologic data nor frequency of previous thrombosis
was significantly different between fibrotic versus prefibro-
tic PMF patients with the exception of age, given that pa-
tients with prefibrotic PMF were significantly younger
(43 years and 61 years; p < 0.019).
During the follow-up period, 2/61 patients with ET
and 8/72 with early PMF had died (p not significant).
Cytoreductive therapy was applied in 51 patients (83%)
with ET and in 64 (88%) with early PMF (p not signifi-
cant) (Table 1). In total overt fibrotic transformations
were documented in one patients (1%) and 3 patients
(4%), respectively, with ET and with early PMF (p not
significant). At 15 years, overall survival was significantly
better in ET than in early PMF, respectively 96% vs 76%
(p = 0.027). Multivariate analysis showed that only age
over 60 years and histology (early PMF) were significant
risk factors for reduced overall survival (p < 0.05).
Progression to overt myelofibrosis and leukemia (PFS)
and death rates were similar between the 2 subgroups of
PMF and ET patients, whereas ET patients showed a sig-
nificantly superior OS only than fibrotic PMF (Figure 2).
During follow-up, patients with prefibrotic PMF, al-
though younger, showed a significant higher risk of de-
veloping thrombosis: the 15-year risk of thrombosis was
48% in prefibrotic PMF, 16% in fibrotic PMF (grade 1, 2)
and 17% in ET (prefibrotic PMF vs fibrotic PMF p = 0.049;
prefibrotic PMF vs ET p = 0.032; Figure 3). Multivariate
analysis confirmed that prefibrotic PMF is an independent
risk factor for cumulative thrombotic events and identified
age older than 60 years as an additional risk factor for
thrombosis (p < 0.05). According to our data, we propose
a new risk score: patients older than 60 or those with pre-
fibrotic PMF are high risk patients, whereas those younger
and with ET and fibrotic PMF should be considered at low
risk. By applying the model to our series at diagnosis, the
development of future vascular events is 34% and 7% for
high and low risk at 15 years (p = 0.005) and 47% and 7%
for high and low risk at 20 years (p = 0.005; Figure 4).riginal magnification x20. In cases considered ET, the cellularity appeared
ei and showed low tendency to aggregate. In cases considered PMF, the
ocytes were aggregated and showed frequently hypolobulated nuclei.
Table 1 Clinico-pathological parameters for patients with
ET and early/prefibrotic PMF
True ET PMF p value
M/F 27/34 26/46 n.s.
Median age (years) 58.0 (23–84) 55.5 (20–87) n.s.
Mean WBC (109/l) 7.5 8.4 p = 0.001
Mean Hb (g/dl) 14.1 14.3 n.s.
Mean PLT (109/l) 751 798 n.s.
Increased LDH (%) 17/45 (37.7%) 18/50 (36.0%) n.s.
Splenomegaly (%) 12 (19%) 18 (25%) n.s.
Mean semiquantitative score
for granulopoiesis
0.15 1.02 p = 0.001
JAK2V617F-positive (%) 11 (33%) 23 (54%) n.s.
History of thrombosis (%) 5 (8%) 16 (22%) p = 0.032
Thrombosis at diagnosis (%) 1 (1.6%) 11 (15.2%) p = 0.006
Thrombotic events during
follow up (%)
7 (11.4%) 11 (15.2%) n.s.
Progression to overt MF (%) 1 (1.6%) 3 (4.1%) n.s.
Dead/alive 2/59 8/64 n.s.
Conventional Risk (Low/High) 35/26 30/42 n.s.
Cytoreductive therapy (%) 51 (83%) 64 (88%) n.s.
Table 3 Clinical characteristics in the two subgroups of






Sex M:F = 11/15 M:F = 15/31 n.s.
Median age at diagnosis
(years)
43 (20–87) 61 (27–83) p = 0.019
WBC at diagnosis (109/l) 9100 8745 n.s.
Hb at diagnosis (g/dl) 14.6 14.3 n.s.
PLT at diagnosis (109/l) 825000 797500 n.s.
Increased LDH 6/19 (31.6%) 19/31 (61.3%) n.s.
Splenomegaly (%) 6 (23%) 12 (26%) n.s.
JAK2V617-positive (%) 9 (50%) 14 (58%) n.s.
History of thrombosis (%) 6 (23%) 10 (22%) n.s.
Thrombosis at diagnosis (%) 4 (15%) 7 (15%) n.s.
Thrombotic events during
follow-up (%)
6 (23%) 5 (10%) n.s.
Progression to overt MF (%) 0 (0%) 3 (6.5%) n.s.
Dead/Alive 2/24 6/40 n.s.
Conventional Risk (Low/High) 13/13 17/29 n.s.
Cytoreductive therapy (%) 24 (92%) 40 (86%) n.s.
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Many literature data, mainly arising from the Cologne
Group, showed that approximately 40% to 50% of pa-
tients with clinical “ET” have an initial stage of PMF pre-
senting with thrombocytosis and characterized by
prominent granulocytic and megakaryocytic proliferation
and significant anomalies of megakaryocytes [10]. In our
study the review of initial bone marrow specimens, con-
firmed ET diagnosis in only 43% and changed to early
PMF in 50% and is in line with these data. The relevance
of a sharp distinction of ET and early PMF is stressed by
clinical results of Barbui et al. in an international-based
data collection of 1104 patients with a clinical phenotype
of ET [2]: WHO-defined ET patients showed a lowerTable 2 Main thrombotic events at diagnosis and during
follow up in ET and PMF












PMF 2 1 1 3 3 1
Thrombotic events during follow-up
ET 2 4 1
PMF 2 2 2 1 1 3
Note: AMI = acute myocardial infarction; TIA = transient ischemic attack;
PAT = peripheral arterial thrombosis; DVT = deep-vein thrombosis; PE = pulmonary
embolism.risk of overt myelofibrosis, AML evolution, and, finally,
a better survival compared with PMF. The discussion on
the reproducibility of the WHO-subjective morpho-
logical criteria is still ongoing, as for many authors these
criteria are not simple to apply [8,9,11], whereas for
others an agreement among pathologists can be achieved
in 88% to 93% of cases [10,12,13]. In our study the issue
of the inter-observer histologic reproducibility was be-
yond our aims, although it may be considered a poten-
tial bias. In reality, as the original diagnoses were made
by a group of general pathologists with different degree
of expertise in the field and were reviewed in approxi-
mately 60% of cases by a single expert hemopathologist
from the same department, we believe that it offers the
perspective of the diagnostic work in the daily-practice
by general practitioners and referral pathologists, point-
ing out the importance of careful clinico-pathological
correlation in patient with MPNs [16].
In our series, at diagnosis, early PMF patients showed
greater leukocyte count, history of thrombosis and throm-
bosis at the onset of disease, than ET patients. Statistical
analysis of morphological features (semiquantitative scoring
system) and clinical data showed a significant correlation
between medullary leukocytosis and thrombosis. Multivari-
ate analysis undoubtedly states that histology (early/prefi-
brotic PMF) is a predictor of reduced survival as well as age
over 60 years. It is well known that Thiele and co-workers
[10] first stated that BM fibrosis is not an intrinsic and ne-
cessary marker of PMF, and proposed a new category of
Figure 2 Overall survival (OS) of patients with ET, prefibrotic PMF and fibrotic PMF. Significant differences were found only between ET and fibrotic PMF
patients (p = 0.027).
Figure 3 Risk of thrombosis during follow-up: the 15-year risk of thrombosis was 48% in prefibrotic PMF, 16% in fibrotic PMF (grade 1, 2) and 17% in ET.
Differences were significant between prefibrotic PMF vs fibrotic PMF (p = 0.049) and between prefibrotic PMF vs ET (p = 0.032).
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Figure 4 Patients older than 60 or with prefibrotic PMF are high-risk patients, whereas those younger and with ET and fibrotic PMF should be considered
at low risk. The resulting risk categories (high or low-risk) better predicted future vascular events than conventional risk factors (34% and 7% respectively for
high and low risk at 15 years; p = 0.005).
Rupoli et al. Diagnostic Pathology  (2015) 10:29 Page 6 of 8patients with dual megakaryocytic and granulocytic myelo-
proliferation associated with characteristic megakaryocyte
dysplasia and absence of relevant reticulin fibrosis in BM.
This variant with BM fibrosis grade 0 was called prefibrotic
myelofibrosis whereas the variant with the BM morpho-
logical features of early PMF but having at least grade 1
fibrosis was categorized into the fibrotic type category of
PMF. In the present study progression (to overt myelofibro-
sis and leukemia) and death rates were similar between the
fibrotic and prefibrotic early PMF, while WHO-ET patients
showed a significantly superior OS than fibrotic PMF. Fur-
thermore, statistical analysis allowed us to recognize that
prefibrotic PMF patients, although younger, presented with
a higher probability of thrombotic events (48%) compared
with WHO-ET (16%) or fibrotic PMF patients (17%). Some
characteristics of our prefibrotic PMF show striking similia-
rities with those that were well-outlined in the series of
Barosi [17,18]. The mobilization of endothelial progenitors
(ECFCs) cells is consistently higher in patients who received
a diagnosis of prefibrotic myelofibrosis, thus giving rise to
the hypothesis that endothelial progenitor cell-mediated
neoangiogenesis, could intervene in determining the dis-
tinctive phenotypic profile of prefibrotic PMF [19]. As for
thrombotic risk, until now, the incidence of thrombosis in
prefibrotic PMF have been rarely assessed. Barbui et al.
[20] showed that the rate of major cardiovascular eventsin PMF was comparable with that reported in ET, and it
was increased in aged patients and those with JAK2V617F
mutation and leukocytosis. Unfortunately in that study,
the so-called “prefibrotic” form of PMF was not consid-
ered. In the same year, Brousseau et al. [9] applied WHO
criteria to bone marrow specimens of patients previously
diagnosed as having ET and observed no clinical (includ-
ing thrombosis) or biologically differences between “true
ET”, prefibrotic and fibrotic PMF. The clinical course of
264 patients with early/prefibrotic PMF was subsequently
studied by Buxhofer-Ausch and co-warkers [21]; the au-
thors suggested the importance of early/prefibrotic PMF
as a distinct sub-entity of MPNs and indicated that
leukocytosis at diagnosis was the preminent risk of total
and arterial thrombosis in particular. Initial bone marrow
reticulin fibrosis also exerts an impact on clinical outcome
in polycythemia vera [22]. Barbui found a significantly
higher occurrence of major thrombotic events during
follow-up, in PV patients without reticulin fibrosis; on the
contrary PV patients with increases in reticulin fibrosis
displayed a higher prevalence of palpable splenomegaly
and were more prone to develop overt myelofibrosis. The
authors speculated that the variant without reticulin fibro-
sis might be characterized by a different biology or that
the higher rate of thrombotic events might be related to a
longer disease duration [22]. The major consequence of
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could be considered acquired thrombophilic conditions,
potentially requiring a new way of therapeutic interven-
tion. Current thrombosis risk factors in ET are age and
previous vascular events [23-26] and mutational status for
JAK2, MPL, and Calreticulin [27]. Our study provides evi-
dence that a morphologic discrimination of prefibrotic
PMF from true ET has a significant impact on the risk of
thrombosis. At multivariate analysis, among the potential
predictors, only age and histopathology remained inde-
pendent risk factors for thrombosis during follow-up. Pa-
tients older than 60 or with prefibrotic PMF are high-risk
patients whereas those younger and with fibrotic PMF or
true ET should be considered low-risk. Whether our new
risk classification may optimize the management of pa-
tients presenting clinically with “ET” needs to be validated
in association with mutational analysis. If prefibrotic PMF
is strongly affected by thrombosis, its recognition might
favor an early intervention at the time of diagnosis, to re-
duce MPN clone-derived prothrombotic features. Prob-
ably it is time to better understand the characteristics of
prefibrotic PMF, change our “wait and watch strategy” [28]
and start an upfront therapy (e.g. IFN-α [29] as monother-
apy or in addition to JAK2-inhibitors) combined with the
treatment of all modifiable factors that increase the vascu-
lar risk [30]. Moreover, the antithrombotic effectiveness of
aspirin, demonstrated in PV and to a lesser extent in ET
[31,32], might be tested in prefibrotic PMF after a careful
evaluation of the individual hemorrhagic risk.
Conclusions
Our study provides further evidence that morphologic fea-
tures of the bone marrow favoring the diagnosis of prefi-
brotic PMF or true ET, have a significant impact on the
risk of thrombosis. Bone marrow histologic examination
should maintain a central role in the diagnostic and thera-
peutic approach of patients with thrombocytemias.
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